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Sugar- and lipid-derived aldehydes are reactive carbonyl species (RCS) frequently used as
surrogate markers of oxidative stress in obesity. A pathogenic role for RCS in metabolic
diseases of obesity remains controversial, however, partly because of their highly diffuse
and broad reactivity and the lack of specific RCS-scavenging therapies. Naturally occurring
histidine dipeptides (e.g., anserine and carnosine) show RCS reactivity, but their
therapeutic potential in humans is limited by serum carnosinases. Here, we present the
rational design, characterization, and pharmacological evaluation of carnosinol, i.e., (2S)-2-
(3-amino propanoylamino)-3-(1H-imidazol-5-yl)propanol, a derivative of carnosine with high
oral bioavailability that is resistant to carnosinases. Carnosinol displayed a suitable ADMET
(absorption, distribution, metabolism, excretion, and toxicity) profile and was determined to
have the greatest potency and selectivity toward a,b-unsaturated aldehydes (e.g., 4-
hydroxynonenal, HNE, ACR) among all others reported thus far. In rodent models of diet-
induced obesity and metabolic syndrome, carnosinol dose-dependently attenuated HNE
adduct formation in liver and skeletal muscle, while simultaneously mitigating inflammation,
dyslipidemia, insulin resistance, and steatohepatitis. These improvements in metabolic
parameters with carnosinol were not due to changes in energy expenditure, physical
activity, adiposity, or body weight. Collectively, our findings illustrate a pathogenic role for
RCS in obesity-related metabolic disorders and provide validation for a promising new
class of carbonyl-scavenging therapeutic compounds rationally derived from carnosine.
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Introduction
Overnutrition from fatty acids and complex carbohydrates is 
known to cause oxidative stress from multiple enzymatic and non-
enzymatic sources due to the high caloric content and the preva-
lence of these macronutrients in the Western diet. A pathological 
role for oxidative stress in obesity has been clearly established 
through extensive clinical and experimental studies. Reactive sug-
ar- and lipid-derived aldehydes (reactive carbonyl species [RCS]) 
are spontaneously formed during the preparation of high-fat/
high-sugar–containing foods under high heat (1) and are formed in 
vivo as a byproduct of oxidative stress. These RCS alter proteins 
via the covalent modifications of cysteine, arginine, lysine, and 
histidine and form adducts with phospholipids and DNA. Glucose- 
derived oxoaldehydes such as methylglyoxal (MGO) accumulate in 
oxidative tissues and react with protein functional groups, forming 
advanced glycation end-products (AGEs) (2, 3). AGEs are a major 
cause of chronic inflammation, cardiovascular disease, diabetes, 
and even some cancers, all of which are associated with obesity 
(4–8). In addition to reducing sugars and sugar-derived breakdown 
products, lipid-derived aldehydes are another significant source of 
carbonyl stress in vivo. Individuals who consume diets rich in veg-
etable and corn oil have very high endogenous levels of n-6 poly-
unsaturated fatty acids (PUFAs). The α,β-unsaturated carbonyls 
derived from n-6 PUFA oxidation have particularly diverse biologi-
cal effects. Of these, 4-hydroxynonenal (HNE) and acrolein (ACR) 
have been the most widely studied (9). These aldehydes rapidly 
form adducts with proteins and phospholipids (10), and chronic 
exposure to high levels of these aldehydes is toxic (11). The accu-
mulation of HNE has been extensively documented in blood and 
tissue samples from obese/diabetic patients, typically as a marker 
of oxidative stress (12–16). However, emerging studies suggest that 
these reactive aldehydes are more than simply by-products of oxi-
dative stress. Rather, the carbonyl-modifying activity imposed by 
these reactive species may have a distinct pathogenic role in obe-
sity-related disorders such as insulin resistance, chronic inflamma-
tion and fibrosis, dyslipidemia, and liver disease (15, 17–23). Thus, 
novel compounds that mitigate the production or enhance the 
removal of RCS remain compelling therapies for cardiovascular 
and metabolic diseases associated with obesity.
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therapeutic compound should: (a) be stable in plasma; (b) effec-
tively scavenge (i.e., trap) circulating RCS; and (c) be highly reac-
tive and selective toward damaging RCS (29). l-carnosine fulfils 
some of the above-mentioned requirements (30). However, it 
lacks an important basic requirement to be a suitable RCS-seques-
tering agent, because it is unstable in the circulation as a result of 
the hydrolytic action of carnosinases.
Hence, the rational design of improved l-carnosine deriva-
tives should be focused on molecules that, besides maintaining or 
even enhancing quenching activity and selectivity, are endowed 
with plasma stability and oral bioavailability. To this end, the ide-
al derivative should: (a) maintain or better optimize its quenching 
activity, at least toward HNE, while preserving its selectivity; (b) 
maintain the active transport by human H+/peptide cotransport-
er-1 (hPepT1); and (c) eliminate recognition by human serum car-
nosinase (30, 31). As depicted in Figure 1A, this can be pursued 
by modifying the carboxyl group, which (a) is not involved in the 
quenching mechanism, even though its complete deletion has a 
detrimental effect, as seen in carcinine; (b) has a crucial role in car-
nosinase-1 (CN1) binding (Figure 1B); and (c) has a marginal role 
in hPepT1 transport (Figure 1C). Reduction of the carboxyl group 
has only a modest impact on the PepT1 interaction (Figure 1C), 
since both the carboxyl and hydroxyl functions elicit comparable 
and (weak) H-bonds with surrounding backbone atoms, as also 
confirmed by very similar interaction energies (–19.056 vs. –17.934 
kcal/mol). In contrast, the carnosine carboxyl group is engaged in 
a pivotal ion pair with Arg350 in CN1 (Figure 1B), and its reduction 
to the hydroxyl function has a dramatic impact on the stability of 
the CN1-carnosinol complex, as confirmed by the reported drop in 
the interaction energy (–22.770 vs. –14.862 kcal/mol).
Given these modeling results, the carboxyl reduction to yield 
carnosinol should meet all the above requirements and should 
l-carnosine is a naturally occurring dipeptide (β-alanyl-histi-
dine), which, along with its analogs, is a potent endogenous scav-
enger of RCS and highly concentrated (mM) in muscle and ner-
vous tissues (24). The utility of l-carnosine as a pharmacological 
agent has been demonstrated in rodent models of metabolic syn-
drome and cardiovascular disease (25–27) and by its widespread 
use as eyedrop therapy in patients with ocular diseases (28). Major 
obstacles exist with respect to the clinical applicability of l-car-
nosine as an oral drug therapy, however. The largest of these is that 
high serum and tissue carnosinase activity in humans abrogates 
the bioavailability of circulating carnosine by rapid hydrolysis of 
the peptide bond (24).
Here, we present the rational design, characterization, and 
pharmacological evaluation of carnosinol, i.e., (2S)-2-(3-amino pro-
panoylamino)-3-(1H-imidazol-5-yl)propanol, a reduced derivative 
of l-carnosine that is impervious to metabolism by carnosinase. 
Carnosinol displayed selectivity for reaction with RCS in vitro and 
in vivo, oral bioavailability and long duration in vivo, and negligible 
toxicity in human cell cultures and animal models. In rodent mod-
els of diet-induced obesity, carnosinol dose-dependently reduced 
systemic carbonyl stress, normalized glycemic control and many 
inflammatory parameters, and mitigated steatohepatitis. Collec-
tively, these findings illustrate a distinct pathological role of RCS 
in metabolic diseases of obesity and validate the use of a novel 
RCS-scavenging l-carnosine derivative to treat these diseases.
Results
Rational design of carnosinol
In addition to the common properties that characterize a drug-like 
molecule (i.e., chemical and metabolic stability, bioavailability, 
and safety), our a priori rationale was that an RCS-sequestering 
Figure 1. In silico models and bio-
chemistry of carnosinol metabolism. 
(A) Structure-activity relationships for 
l-carnosine and comparison with car-
nosinol. (B) Putative complex between 
carnosinol and CN1, highlighting the 
missing ion pair with Arg350 when com-
pared with the corresponding complex 
for l-carnosine. (C) Putative complex 
between carnosinol and hPepT1, reveal-
ing that the inserted hydroxyl group 
elicits H-bonds similar to those already 
observed for l-carnosine.
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amine. We found carnosinol to be less effective 
only by comparison with hydralazine, a commonly 
prescribed antihypertensive medication with non-
selective RCS reactivity, as shown by its effects 
with pyridoxal. In contrast, we found that carnosi-
nol did not react with pyridoxal, and hence it can 
be considered a selective RCS-sequestering agent, 
like the parent compound l-carnosine.
The mechanism of carnosinol reaction toward 
HNE was fully elucidated on the basis of the reac-
tion products identified and characterized by 
mass spectrometry (MS) experiments (Supple-
mental Figure 1). The proposed reaction mecha-
nism (Figure 2A) is similar to that already clarified 
for l-carnosine and based on the formation of an 
imine derivative (CI) that catalyses the Michael 
adduct (CII) (Figure 2B).
The increased potency of carnosinol com-
pared with that of l-carnosine can be explained by the favorable 
stereoelectronic parameters as predicted by quantum mechani-
cal simulations (Supplemental Table 1) and also by the ability of 
the hydroxyl group to form a hemiacetal intermediate with HNE, 
which, in addition to the amino group of β-alanine, further catalyz-
es the formation of the Michael adduct.
The quenching ability of carnosinol to inhibit HNE induced 
protein covalent adducts, and its comparison with the known 
quenchers was then evaluated in a MS-based assay that was recent-
ly set up in our laboratory (33). The assay consists of determining 
the ability of the tested compounds to inhibit the formation of 
HNE-induced adducts on a target protein, human ubiquitin, whose 
carbonylation specifically involves Lys6 and His68. Shown in Figure 
3 is the MS spectrum of ubiquitin incubated in the absence and pres-
ence of HNE, inducing the formation of an HNE Michael adduct 
characterized by a molecular weight (MW) shifted by 156 kDa with 
respect to native ubiquitin. Carnosinol dose-dependently inhibited 
ubiquitin carbonylation. The greater activity with respect to hydral-
azine when measured via HPLC as compared with MS can be easily 
explained by considering that hydralazine forms a reversible Schiff 
base with HNE, as already reported (30), that cannot compete with 
the formation of Michael adducts on ubiquitin. By contrast, the 
more stable carnosinol-HNE adduct is not shifted in the presence 
of ubiquitin; thus, hydralazine was less efficient when tested by MS. 
The percentage of inhibition of HNE-induced ubiquitin carbonyla-
tion for carnosinol and some selected reference compounds are also 
reported in Table 1. Note again that hydralazine depletes pyridoxal 
levels completely, a feature of this drug that undoubtedly contrib-
utes to the adverse risk profiles related to vitamin B deficiency.
We then used both HPLC and MS to test carnosinol seques-
tering activity toward MGO and MDA (Supplemental Figures 2 
and 3 and Table 2). We found carnosinol to be more effective as a 
MGO-sequestering agent than l-carnosine and of the same order 
of potency of well-established scavengers such as aminoguanidine 
and hydralazine. An adduct characterized by a methylglyoxal- 
lysine dimer –like (MOLD-like) structure was identified by MS as 
the major reaction product between carnosinol and MGO (Sup-
plemental Figure 2). The sequestering activity toward MDA was 
found superimposable with respect to carnosine, and the N-prope-
even enhance the quenching activity, since it optimizes some 
physicochemical parameters that influence the quenching mech-
anism (e.g., flexibility and lipophilicity). Besides a greater flexibil-
ity, physicochemical analysis reveals that carnosinol is also more 
lipophilic than carnosine, as seen in experimental log P and log 
D7.4 values, a property that would benefit the molecular engage-
ment by lipophilic RCS (Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI94307DS1). Furthermore, carboxyl reduction did not sig-
nificantly affect the ionization constant or the chelating activity 
toward transition metal ions such as Cu2+, which are roughly com-
parable to those of carnosine (chelating activity of Cu2+ [pKCuHL] = 
12.73, [pKCuL] = 5.49). Quantum mechanical simulations showed 
that carnosinol also possesses favorable stereoelectronic parame-
ters (Supplemental Table 1).
Carnosinol is a selective and potent RCS-sequestering agent
We first performed in vitro testing of the sequestering activity of 
carnosinol toward the most widely studied RCS involved in oxi-
dative-based diseases and belonging to the chemical classes of 
α,β-unsaturated aldehydes, i.e., 4-hydroxynonenal (HNE), ACR 
dialdehydes, i.e., malondialdehyde (MDA) and glyoxal (GO), and 
ketoaldehydes, i.e., MGO.
Sequestering of HNE. The sequestering activity of carnosinol 
toward HNE and ACR was first evaluated and compared with 
l-carnosine and for other small molecules known to possess sim-
ilar properties (32). We directly compared carnosinol reactivity 
toward ACR and HNE with the reactivity of l-carnosine toward 
these aldehydes. Both compounds effectively reduced free alde-
hyde levels via conjugate formation over time, but interestingly, 
carnosinol showed a more rapid depletion of both ACR and HNE 
during the incubation compared with l-carnosine (Supplemental 
Table 2). We then determined selectivity by comparing carnosinol 
reactivity with HNE and the biogenic aldehyde pyridoxal (Table 1). 
The data are reported as consumption percentages (Q% ± SD) of 
HNE after 24 hours and consider a quencher/RCS ratio of 1:1 for 
HNE and 10:1 for pyridoxal (30). Carnosinol was the most reac-
tive compound with respect to l-carnosine and other well-known 
RCS-sequestering agents such as aminoguanidine and pyridox-
Table 1. Comparison of carnosinol reactivity with HNE and the biogenic aldehyde 
pyridoxal, reported as consumption percentages (Q% ± SD)  
Compound HNE Pyridoxal
HPLC (Q% ± SD) MS (Q% ± SD) HPLC (Q% ± SD)
l-carnosine 37.3 ± 2.3 25.4 ± 3.7 0.1 ± 0.9
Carnosinol 61.5 ±1.9 38.1 4.0 0.1 ± 0.1
Pyridoxamine 2.1 ± 0.5 0.0 ± 3.4 2.1 ± 0.1
Hydralazine 87.2 ± 3.2 15.2 ± 3.3 100.0
Aminoguanidine 2.3 ± 0.7 3.9 ± 3.2 12.8 ± 0.1
HPLC Q% values express the percentages of the reacted target aldehyde in the presence of 
the tested quenchers after a 24-hour incubation, with a molar ratio of quencher/aldehyde 
equal to 1:1 (HNE) or 10:1 (pyridoxal). MS Q% values express the percentage of inhibition 
of carbonylated ubiquitin induced by HNE after a 24-hour incubation, with a molar ratio of 
quencher/aldehyde equal to 1:1 (HNE).
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reduces atherogenesis (27, 34, 35), dyslipidemia, and renal dys-
function (25) in rodent models of cardiometabolic disease. To 
determine whether carnosinol retained or surpassed the efficacy 
of l-carnosine, we tested the effect of low-dose (10 mg/kg/day) 
and high-dose (45 mg/kg/day in the drinking water) carnosinol on 
cardiometabolic and inflammatory parameters using a short-term 
intervention (3 weeks) in rats fed a high-fructose (HF) diet (60% in 
the food pellet) (Figure 4A). An additional group of rats was treat-
ed for an equivalent period with a clinically relevant dose of rosigl-
itazone, the PPAR agonist widely prescribed for the treatment of 
metabolic syndrome and type 2 diabetes and which we recently 
determined to be a very effective therapy in this model (36). HF 
feeding led to significant gains in body weight (Figure 4B and Sup-
plemental Table 3) compared with control-fed rats, and drug treat-
ment did not cause significant differences in body weight gains. 
Total food and water intake was similar between the groups. Sys-
tolic blood pressure was substantially higher in fructose-fed rats, 
and this was dose-dependently reduced by carnosinol to levels 
comparable to those seen with rosiglitazone (Supplemental Table 
3). This improvement in blood pressure with carnosinol mirrors 
the effect of l-carnosine supplementation on these parameters in 
similar models (25, 26).
Next, we sought to examine the effect of carnosinol on markers 
of systemic oxidative and inflammatory stress. Notably, carnosi-
nol dose-dependently reduced serum AGEs (Figure 4C), urinary 
8-isoprostanes (Table 3), and proinflammatory cytokines (Figure 
4, D–F) in fructose-fed rats. Importantly, the beneficial effects 
of carnosinol treatment on oxidative and inflammatory stress 
were paralleled by improvements in metabolic parameters. Car-
nosinol treatment led to dose-dependent reductions in serum tri-
nal derivative of carnosinol was identified as the reaction product 
(Supplemental Figure 3).
Taken together, the data indicate that carnosinol is selective 
and very reactive toward biogenic sugar- and lipid-derived alde-
hydes and the most potent RCS-sequestering agent among those 
commercially available.
ADMET studies
Carnosinol was evaluated in in vitro ADMET studies as well as 
in exploratory pharmacokinetic (PK) and toxicological studies 
(additional information is available in the supplemental materi-
al). Carnosinol was found to be stable in human serum for at least 
60 minutes, as well as in rat and human liver preparations, thus 
indicating that it is not hydrolyzed by carnosinases. In vitro exper-
iments indicated a good safety profile of the compound (no inhi-
bition of the most important isoenzymes of cytochrome P450, no 
interaction with hERG K+ channel, no cell toxicity up to 100 μM 
concentration in a human hepatoma cell line). We then confirmed 
the safety profile of carnosinol in rats in both single-and repeat-
dose oral toxicity studies. PK studies in rats showed a moderately 
good oral bioavailability that gave a significant exposure in plasma 
after oral administration at a dose of 45 mg/kg.
The data reported above demonstrate that carnosinol ful-
fils the optimization requirements we took into account in the 
rational design.
Dose-dependent effects of carnosinol on systemic inflammation and 
metabolic derangements in fructose-fed rats
Prior studies by our group and others have demonstrated that 
oral administration of l-carnosine and its derivatives effectively 
Figure 2. Carnosinol is a selective sequestering agent of HNE. (A) 
Proposed reaction mechanism of carnosinol (m/z = 213) with HNE (MW = 
156 kDa). Carnosinol, like l-carnosine, reacts with HNE through a 2-step 
mechanism. The reaction starts with the formation of a reversible Schiff 
base (an α,β-unsaturated imine, CI) to yield the macrocyclic adduct 
through an intramolecular Michael addition, which hydrolyzes to form the 
stable hemiacetal derivative CII. (B) Mass spectrum of the reaction mixture 
of carnosinol with HNE incubated for 24 hours at 37°C, characterized by the 
peaks at m/z = 213, attributed to the carnosinol; m/z = 351, attributed to 
the Schiff base (CI); and m/z = 369, attributed to the Michael adduct (CII).
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fat/high-sucrose (HFHS) diet (15). These cardiometa-
bolic disorders in GPx4+/– mice were accompanied by 
extensive carbonyl stress in liver and heart, and cardiac 
mitochondria in obese GPx4+/– mice had decreased fatty 
acid–supported respiration and increased ROS produc-
tion compared with obese WT mice. These results are 
consistent with mitochondrial localization of GPx4 and 
its known role in protecting mitochondria from oxidative 
stress (40). Importantly, diabetic patients have higher 
levels of HNE adducts and lower GPx4 enzyme levels 
in their myocardial tissue compared with nondiabetic 
patients (15), a finding that corroborates previous obser-
vations concerning HNE adducts in diabetic patients 
(12–14, 16). Thus, GPx4+/– mice are ideal for the pharma-
cological evaluation of carnosinol, because much of the 
underlying stress-induced pathology of these mice is due 
to oxylipid-derived aldehydes.
To determine whether carnosinol is effective at 
mitigating obesity-related metabolic disorders, we 
administered the compound at the high dose (45 mg/kg/day in 
the drinking water) in a cohort of HFHS diet–induced obese WT 
mice. Given our previous findings in GPx4+/– mice on a HFHS 
diet, a cohort of GPx4+/– mice was used in parallel with WT mice 
to allow for assessment of carnosinol in a clinically relevant, 
translational model of severe carbonyl stress. Drug was admin-
glycerides and cholesterol (Figure 4, G and H), improved glycemic 
control (Figure 4, I and J), and mitigated liver toxicity (Figure 4K) 
and steatosis (Table 3) induced by fructose feeding. All improve-
ments in systemic metabolic and inflammatory parameters with 
carnosinol treatment were paralleled by significant reductions 
in plasma (Figure 4, L and M), kidney, and liver of HNE adducts 
(Supplemental Figure 4). Liver and renal fibrosis were not 
significantly affected by fructose feeding or drug treatment 
(data not shown), although the urinary creatinine clearance 
rate decreased with fructose feeding (Table 3), and this effect 
was blunted with carnosinol and rosiglitazone treatment.
Carnosinol improves glycemic control and muscle insulin 
sensitivity in mouse models of severe carbonyl stress and  
diet-induced obesity
Glutathione peroxidase 4 (GPx4), also named phospholip-
id hydroperoxide glutathione peroxidase, is the only known 
selenoenzyme that exclusively neutralizes lipid peroxides in 
membranes and lipoproteins (37). Homozygous null GPx4 
mice die around gestational day 7, underscoring the critical 
role for this enzyme in development. GPx4-haploinsufficient 
(GPx4+/–) mice have approximately 40% of the WT GPx4 
enzyme levels in oxidative tissues and are highly susceptible 
to environmental stressors due to enhanced lipid peroxidation 
and protein carbonylation (38, 39). Recently, we observed that 
GPx4+/– mice displayed exacerbated metabolic derangements 
and cardiomyopathy when fed an n-6 PUFA–enriched, high-
Figure 3. Carnosinol inhibits HNE-induced ubiquitin carbon-
ylation. (A) MS spectrum of ubiquitin control sample focusing 
on the z = 11 multicharged ion peak at m/z = 779; (B) 11+ peaks 
obtained upon incubation of ubiquitin with HNE, corresponding 
to unmodified (m/z = 779) and HNE-modified (m/z = 793) forms 
of the protein. (C and D) 11+ peaks obtained upon incubation of 
ubiquitin with HNE and carnosinol at 2 different molar ratios: 
HNE/carnosinol 1:0.5 mol/mol (C) and HNE/carnosinol 1:1 mol/
mol (D), showing reduced intensity for the peak corresponding 
to the modified protein (m/z = 793).
Table 2. HPLC and MS testing of carnosinol sequestering activity toward 
MGO and MDA
Compound MGO MDA
HPLC (Q% ± SD) MS (Q% ± SD) UC50
l-carnosine 12.8 ± 1.6 4.1 ± 0.6 4 ± 0.4
Carnosinol 36.4 ± 1.6 13. 6 ± 2.1 3.8 ± 0.3
Pyridoxamine 2.5 ± 1.4 0.1 ± 0.1 1.3 ± 0.1
Hydralazine 48.6 ± 4.2 14.2 ± 2.0 3.1 ± 0.5
Aminoguanidine 34.7 ± 2. 7 11.3 ± 2.0 9.4 ± 0.7
HPLC Q%, fraction (percentage of total) of aldehyde quenched after a 24-hour 
incubation; MS Q%, percentage of carbonylated ubiquitin formation inhibited 
by the tested compounds; UC50, concentration required to inhibit MDA-induced 
ubiquitin carbonylation by 50%. Carnosinol activity was compared with that 
of carnosine and of well-known RCS-sequestering agents. MGO activity was 
evaluated by HPLC and MS assays and the dose-dependent activity toward MDA 
by MS. Data for the quenching activity of l-carnosine, pyridoxamine, hydralazine, 
and aminoguanidine toward MDA and MGO are from ref. 30.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
5 2 8 5jci.org   Volume 128   Number 12   December 2018
istered to mice starting after 8 weeks on the HFHS diet, and a 
control group was fed normal chow for the duration of the study 
(Supplemental Figure 5A). As expected, the HFHS diet increased 
body weights and adiposity in both WT and GPx4+/– mice (Sup-
plemental Figure 5, B and C), and carnosinol had no effect on 
these parameters, although fasting serum triglyceride and cho-
lesterol levels were decreased in the carnosinol-treated mice 
(Supplemental Table 4). We detected no effect of carnosinol on 
whole-body energy expenditure (Supplemental Figure 6) or food 
or water intake (data not shown) in mice compared with those 
on a HFHS diet alone. Carnosinol treatment led to enhanced 
glucose disposal following oral glucose challenge in obese WT, 
but not GPx4+/–, mice (Figure 5, A–C). This improved glucose 
disposal may be attributed in part to increased skeletal muscle 
insulin sensitivity, as carnosinol normalized insulin-stimulated 
2-deoxyglucose (2-DOG) uptake in extensor digitorum longus 
(EDL) to levels similar to those in control-fed lean mice (Figure 
5D), although this effect was not seen in soleus (Figure 5E). We 
observed no improvement in insulin sensitivity with carnosinol 
in soleus tissue from obese WT mice, although we observed a 
modest improvement in obese GPx4+/– soleus (Figure 5F).
Reactive aldehyde derivatives of lipid peroxidation have 
recently come into focus as novel redox signaling agents that, para-
doxically, have beneficial and pathological roles, depending on the 
concentration and tissues and cells affected (11, 41). Protein-HNE 
adducts are known to be increased in skeletal muscle of type 2 dia-
betic and obese/insulin-resistant patients, and these adducts are 
associated with the severity of insulin resistance (42). Experimen-
tal models have reported that lipid peroxidation in skeletal mus-
cle blunts insulin signaling and glucose uptake in skeletal muscle 
Figure 4. Dose-dependent mitigation of inflammation and metabolic disease parameters by carnosinol in HF diet–fed rats. (A) Study design for HF 
diet–induced metabolic disease in a rat model. The effect of either a HF diet alone or in combination with low-dose (10 mg/kg) or high-dose (45 mg/
kg) carnosinol or rosiglitazone in the drinking water on overall changes in body weight (B) and the levels of serum AGEs (C), TNF-α (D), IL-6 (E), C-reactive 
protein (F), triglycerides (G), cholesterol (H), glucose (I), and insulin (J). Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (K), 
along with liver triglycerides (L) and liver cholesterol (M) levels, are also shown. †P < 0.01 versus control diet; §P < 0.01 versus HF diet alone; *P < 0.01 versus 
HF plus carnosinol (10 mg/kg); 1-way ANOVA using a Newman-Keuls post hoc test for multiple comparisons (n = 6).
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via HNE adduct formation (43, 44). Lipid peroxidation and HNE 
adduct formation have also emerged as potential causal factors in 
hyperinsulinemia and the eventual loss of pancreatic β cell func-
tion in models of obesity/overnutrition (45–47), which is further 
evidence of a system-wide pathological role for reactive aldehydes 
in metabolic syndrome. Here, HNE adduct formation in mixed gas-
trocnemius skeletal muscle (Figure 5, F and G) and pancreas (Fig-
ure 5, H and I) increased with a HFHS diet, particularly in GPx4+/– 
mice. Carnosinol effectively mitigated the accumulation of these 
adducts in both WT and GPx4+/– mice on a HFHS diet, suggesting 
that this may be one aspect of the mechanism by which carnosinol 
improves systemic glycemic control in obese mice.
Liver inflammation and fibrosis are mitigated by carnosinol in mouse 
models of severe carbonyl stress– and diet-induced obesity
Nonalcoholic steatohepatitis (NASH) is among a cluster of obe-
sity-related pathologies and is closely linked with insulin resis-
tance. NASH is distinct from fatty liver disease, in that intralobular 
inflammation and fibrosis are present in addition to the steatosis 
(48). The fibrosis component of this disease has been specifical-
ly identified by numerous studies to be the most likely to predict 
adverse outcomes in patients (49). Thus, therapeutic strategies that 
specifically target liver inflammation and fibrosis in obese patients 
will be highly valued by clinicians (50). A number of studies have 
implicated RCS as having a causal role in NASH, due in large part 
to the known effect of RCS on activation of the proinflammatory 
receptor for AGEs (RAGE) pathway (22, 51). In the recent study 
from our group, obese GPx4+/– mice were found to have elevated 
RAGE expression in their heart tissue, and this corresponded to 
greater cardiac inflammatory cytokine expression and fibrosis (15). 
In the present study, RAGE expression in liver was unchanged in 
WT and GPx4+/– mice on a HFHS diet, but carnosinol significantly 
decreased RAGE expression in both groups (Figure 6A). Expression 
of the proinflammatory cytokines TNF-α and IL-6 was significantly 
higher in the livers of HFHS-fed mice, and carnosinol mitigated the 
expression of TNF-α, but not IL-6, in this tissue (Figure 6, B and C).
To further examine the effect of carnosinol on liver patholo-
gy in obesity, sections of liver tissue were fixed and stained with 
oil red O and Picrosirius red to label triglycerides and collagen, 
respectively. As in the previous study, we observed that the HFHS 
diet increased liver triglyceride content in WT and GPx4+/– mice, 
with substantially greater lipid deposition occurring in the obese 
GPx4+/– mice (Figure 6, D and E). Interestingly, we found that the 
increase in liver triglyceride deposition with a HFHS diet was not 
accompanied by changes in serum triglycerides (Supplemental 
Table 4), although this could be attributable to necropsy being 
performed while the mice were in a fasted state. Although total 
triglyceride content in liver did not significantly change with car-
nosinol (data not shown), we observed a shift from predominantly 
macro- to microvesicular steatosis with carnosinol treatment in 
obese WT and GPx4+/– mice (Figure 6E). Carnosinol also blunted 
fibrosis in the liver as indicated by Picrosirius red staining (Figure 
6F). In order to determine whether a HFHS diet and/or carnosi-
nol treatment alters collagen cross-linking in the tissue, we mea-
sured the ratio of insoluble to soluble hydroxyproline quantity 
in liver extracts. A HFHS diet led to an increase in the insoluble 
hydroxyproline fraction in WT and GPx4+/– livers (Figure 6G), and 
carnosinol normalized these levels. Indeed, carnosinol treatment 
was associated with significantly lower levels of collagen overall, 
including soluble hydroxyproline content (Figure 6H), regard-
less of diet or genotype. This decrease in collagen content caused 
by carnosinol treatment in obese WT and GPx4+/– mice does not 
appear to be due to decreased collagen gene expression, as we 
detected no effect of carnosinol on collagen-1 (Figure 6I) or colla-
gen-4 (not shown) mRNA levels.
Pharmacodynamics and reactivity of carnosinol in mouse models  
of obesity and in human serum
In order to ascribe the beneficial effects of carnosinol in our obese 
mouse models to its aldehyde-scavenging capacity in vivo, we 
developed a high-resolution liquid chromatography-MS–based 
(LC-MS-based) approach to measure free carnosinol and carnosi-
nol-aldehyde adducts in biological material. Pooled samples of tis-
sue from skeletal muscle, pancreas, liver, kidney, and adipose tissue 
were analyzed using this method, and free carnosinol was found to 
be detectable only in liver, kidney, and adipose tissue (Supplemen-
Table 3. Hepatic and renal parameters in a HF-fed rat model
Control diet HF HF + carnosinol (10 mg/kg) HF + rosiglitazone (10 mg/kg) HF + carnosinol (45 mg/kg)
Liver weight (g) 13.24 ± 0.43 17.26 ± 0.87 16.47 ± 1.51 13.97 ± 0.67 14.81 ± 0.85
Liver weight (g/100 g body weight) 3.26 ± 0.07 3.85 ± 0.14 3.78 ± 0.28 3.37 ± 0.11 3.51 ± 0.13
Hepatic total lipids (mg/g liver) 27.4 ± 2.5 41.1 ± 3.0A 38.8 ± 3.9A 34.9 ± 3.7 31.9 ± 2.6
Hepatic triglycerides (μmol/g liver) 20.8 ± 2.2 43.6 ± 3.0A 38.4 ± 3.8A 30.3 ± 3.1B 28.5 ± 2.4B
Hepatic total cholesterol (μmol/g liver) 5.3 ± 0.5 9.8 ± 0.8A 9.1 ± 0.7A 7.5 ± 0.6 6.4 ± 0.5B
Right kidney weight (g) 1.26 ± 0.07 1.40 ± 0.06 1.36 ± 0.08 1.28 ± 0.09 1.30 ± 0.08
Left kidney weight (g) 1.23 ± 0.07 1.35 ± 0.06 1.32 ± 0.07 1.25 ± 0.07 1.27 ± 0.06
Urinary volume (ml/day) 11.9 ± 1.1 15.8 ± 1.5 11.5 ± 1.4 13.0 ± 1.7 10.6 ± 2.0
Urinary albumin (mg/day) 34.1 ± 3.1 297.8 ± 28.2A 265.4 ± 24.8A 87.4 ± 7.6A 102.1 ± 8.9A
Urinary protein (mg/day) 72.8 ± 6.0 378.6 ± 22.9A 320.4 ± 24.9A 153.4 ± 13.5A,B 175.8 ± 11.0A,B
Urinary creatinine (mg/day) 138.9 ± 9.9 98.4 ± 6.8A 108.8 ± 6.2 121.4 ± 9.5 132.6 ± 10.3B
Urinary 8-isoprostane (ng/day) 58.6 ± 5.0 149.4 ± 7.9A 130.2 ± 13.5A 136.5 ± 12.6A 108.4 ± 7.6A,B
Data represent the mean ± SEM (n = 6 per group). AP < 0.01 versus control diet; BP < 0.01 versus HF.
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Tandem mass spectra of the signal at 269.16 from traces in Fig-
ure 7A were able to confirm the structure of the putative adduct 
(Supplemental Figure 7). No signal of adducts with other reactive 
carbonyl species (e.g., HNE, HHE, malondialdehyde) were detect-
able in control or carnosine-supplemented animals. This may be 
due to the instability of carnosinol-HNE adducts in liver homoge-
nate, which we determined in separate experiments. Only 63.24% 
± 3.47% of an initial amount of 5 μM carnosinol-HNE conjugate 
was detectable after a 2-hour incubation in liver homogenate, with 
an estimated half-life of 3 hours according to a first-order decay 
model. We did not observe this instability with the carnosinol-ACR 
adduct in liver homogenate.
To further characterize carnosinol reactivity and the stability 
of aldehyde adducts, we tested the HNE-scavenging capacity of 
carnosinol in human serum by spiking the serum with a known 
tal Table 5). We found that carnosinol levels in liver and kidney were 
lower in the HFHS-fed GPx4+/– mice than in the WT mice.
Importantly, the lower concentration of free carnosinol in 
these mice corresponded with a higher concentration of carnosi-
nol-ACR adducts in the liver as compared with concentrations 
in HFHS-fed WT mice treated with carnosinol (Figure 7A). Spe-
cifically, a signal at 269.16082 (i.e., the expected m/z value for 
the carnosinol-ACR Michael adduct) was detectable at the same 
retention time observed in a reference sample prepared by spik-
ing an aliquot of carnosinol-ACR adduct in rat liver homogenate 
at a final concentration of 0.5 μM (Figure 7A, bottom). The narrow 
mass range considered for extracting the chromatograms in Fig-
ure 7A (i.e., 1 ppm mass tolerance) and the reproducible retention 
time if compared with a spiked sample are conclusive evidence of 
the formation of a carnosinol metabolite after supplementation. 
Figure 5. Therapeutic effect of carnosinol on metabolic homeostasis and carbonyl stress in mouse models of diet-induced obesity. The effect of a HFHS 
diet with and without carnosinol treatment is shown for glucose tolerance (A–C, n = 8) and insulin sensitivity of EDL (D) and soleus muscle (E) tissue 
upon termination of the study for each group (n = 6). Representative immunoblots for HNE adducts in whole-tissue homogenates prepared from mixed 
gastrocnemius skeletal muscle (F) and pancreas (H) tissue (n = 3 mice per group), along with the corresponding densitometric analysis (G and I). †P < 0.01 
versus control diet within each respective genotype. A 2-way ANOVA followed by Tukey’s multiple comparisons test was used to test for the main effect of 
the treatment within each genotype.
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yl stress plays a causal role in the metabolic disorders of obesity 
has remained unclear, however. In the present study, we sought 
to investigate the pathological role of RCS in obesity with a ratio-
nal design and pharmacological evaluation of carnosinol, a chem-
ical analog of l-carnosine with high oral bioavailability and a 
RCS-scavenging capacity. Following the design and characteriza-
tion of carnosinol, we performed a comprehensive set of in vitro 
and in vivo studies profiling its effects across a range of experi-
mental models, including rodent models of diet-induced obesity 
and metabolic syndrome. Our findings support the hypothesis that 
sugar- and lipid-derived RCS have a causal role in metabolic dis-
orders associated with obesity. Moreover, we show that carnosinol 
concentration of preformed carnosinol and HNE as well as with 
carnosinol alone. Using our high-resolution LC-MS approach, we 
found that not only was carnosinol-HNE detectable, but unlike in 
tissues, the adduct was highly stable in human serum, with more 
than 85% of the carnosinol-HNE adduct remaining after a 2-hour 
incubation (Figure 7B and Supplemental Figure 8). Moreover, 
carnosinol can form adducts with trace amounts of HNE that are 
already present in human serum.
Discussion
An association between sugar- and lipid-derived RCS and obesi-
ty has been known for many years. The extent to which carbon-
Figure 6. Carnosinol effect on liver inflammation and steatosis in mouse models of diet-induced obesity. Expression of the proinflammatory genes 
RAGE (A), TNF-α (B), and IL-6 (C) in the livers of mice from each treatment group was determined by quantitative reverse transcription PCR (qRT-PCR). 
Representative images of liver histology showing H&E staining (D), oil red O staining of triglycerides (E), and Picrosirius red staining under polarized light 
for collagen/fibrosis (F) in mice from each treatment group. Original magnification, ×100; scale bars: 10 μm. Both insoluble (G) and soluble (H) forms of 
liver hydroxyproline were quantified, along with expression of collagen 1a1 (Col1a1), determined by qRT-PCR (I). Quantified data are shown as the mean ± 
SEM (n = 6/group). †P < 0.01 versus control diet for each respective genotype. A 2-way ANOVA followed by Tukey’s multiple comparisons test was used to 
test for the main effect of treatment within each genotype.
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53). Thus, the effect of carnosinol on RCS in adipose tissue, and 
the resulting impact on metabolic parameters, may have played a 
significant role in the outcomes of the present study.
Though it is clear that lipid peroxidation and RCS do indeed 
have deleterious effects in the context of obesity, there are also 
complex time-, concentration-, and tissue-dependent factors 
to consider. Studies in pancreatic β cells have shown that short-
term exposure to low levels of lipid peroxidation and subsequent 
4-hydroxyalkenal formation stimulates an adaptive response 
mediated by PPARδ, which causes increased glucose-stimulated 
insulin secretion (46, 47). In a previous study, we found that 
numerous enzymes involved in redox buffering and fatty acid 
metabolism are enhanced in rat myocardium in parallel with 
lipid peroxidation following 12 weeks of a HFHS diet (54). Such 
a “hormetic” effect of oxidative stress has been documented by 
other groups using similar obese models (55). Certainly, much 
remains to be determined about the precise mechanisms and fac-
tors involved in lipid peroxidation and subsequent RCS in obesity.
A major determinant of lipid peroxidation now known to be 
intimately involved in regulating disease pathology is the expres-
sion and activity of the selenoenzyme GPx4. As 1 of only 3 antiox-
idant enzymes essential for development (56), GPx4 has recently 
been the target of intense scrutiny by investigators. In particular, 
a critical role for GPx4 in regulating ferroptosis and subsequent 
organ failure has been reported (57–61). Furthermore, genetic 
variants of gpx4 that result in diminished activity and/or enzyme 
content are associated with obesity and cardiovascular disease 
in humans (62–64). We previously reported that GPx4-deficient 
(GPx4+/–) male mice acquire severe insulin resistance, steatohepa-
titis, and cardiomyopathy on a HFHS diet and that diabetic patients 
have diminished GPx4 content and elevated HNE adduct levels in 
their heart tissue compared with levels in age-matched nondiabet-
represents a promising lead compound in a new class of RCS-scav-
enging agents derived from the histidyl dipeptide l-carnosine.
Recently, several important studies involving experimental 
and clinical models have illustrated the unique pathological role of 
lipid-derived aldehydes, particularly HNE, in the development of 
cardiometabolic disease. A study in healthy lean men determined 
that 1 week of a high-fat/high-carbohydrate (i.e., hypercaloric) 
diet induced systemic insulin resistance and glucose intolerance. 
Importantly, the authors showed that HNE modification of glucose 
transporter-4 (GLUT4) in adipocytes, on a residue near the glu-
cose transport channel, played a role in diminished glucose uptake 
following the hypercaloric diet (20). Other studies have shown lip-
id peroxidation and HNE to be mediators of chronic inflammation 
and insulin resistance in adipose tissue (12, 19, 52) and skeletal 
muscle (42, 43) in obesity. From a mechanistic standpoint, the 
most important outstanding question involves the temporality and 
tissue dependency of RCS. Specifically, it is still unclear how long 
the oxidative stress must persist after the onset of caloric overload 
in order for RCS pathogenicity to emerge. Moreover, it is still not 
clear whether RCS are equally toxic and pathogenic in every tis-
sue. Considering the critical role of the liver, skeletal muscle, and 
adipose tissue in glucose disposal and intermediary metabolism, 
these organs represent the most obvious target for examination. 
For example, a likely explanation for the decrease in serum and 
liver triglycerides with carnosinol treatment in the rodent models 
is that this effect is secondary to the improvement in insulin sen-
sitivity and glycemic control. It is also noteworthy that in the car-
nosinol-treated mice, adipose tissue retains the highest concentra-
tion of the drug, behind liver and kidney tissue. Although adipose 
tissue was not a major focus of this study, much work over the past 
decade has documented the presence and pathogenicity of RCS 
in adipose tissue as it pertains to metabolic syndrome (12, 19, 52, 
Figure 7. Pharmacodynamics and aldehyde-scavenging capacity of carnosinol. LC-MS analyses were performed on pooled, prepared liver homogenates 
from WT and GPx4+/– mice from each of the treatment groups. (A) Single-ion chromatograms of the carnosinol-ACR adduct (269.16082 m/z, ± 1 ppm). The 
bottom trace in A is the reference standard used in this analysis and was prepared by spiking rat liver homogenate with 0.5 μM carnosinol-ACR adduct. (B) 
LC-MS analysis showing the single-ion chromatogram of carnosinol-HNE adducts in human serum spiked with carnosinol and HNE (top), carnosinol only 
(middle), and serum only. Values shown in the green boxes denote the corresponding concentration of these adducts.
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increased enzyme activity (and, consequently, lower serum l-car-
nosine levels) is linked to diabetic nephropathy (72). Transgenic 
db/db mice overexpressing human CN1 and having reduced serum 
carnosine levels exhibit higher fasting plasma glucose and HbA1c 
levels, to the extent that the glucosuria in these mice causes a 
significant reduction of body weight (73). It can be inferred from 
these studies that serum l-carnosine levels are directly linked to 
glycemic control and that human CN1 presents an attractive drug 
target for this patient population.
Our group envisioned 2 approaches that could circumvent 
the challenge posed by endogenous carnosinases: (a) inhibition 
of these enzymes during simultaneous oral l-carnosine therapy; 
and (b) design of stable carnosine peptide mimetics resistant to 
carnosinases. The former approach was not pursued because of a 
high potential for toxicity, as CN1 is critical for neurotransmitter 
production, histidine metabolism, and other vital functions. To 
address the latter approach, we previously synthesized and char-
acterized the carnosinase-resistant enantiomer d-carnosine and 
found that this compound exhibited a significant RCS-scaveng-
ing effect in vitro and in vivo, but had poor intestinal absorption 
due to a low affinity for and transport by PepT1 (74). Other groups 
have successfully made carnosine derivatives that are resistant to 
carnosinase and initially showed therapeutic potential, but failed 
in preclinical testing largely because of decreased absorption (75, 
76). An octylester derivative of d-carnosine showed enhanced 
intestinal absorption and therapeutic effects in a mouse model 
of cardiometabolic disease (34), but the translational applicabil-
ity of this compound is low because of potency issues that likely 
stem from dosing limitations resulting from diminished absorp-
tion. Carnosinol is the most promising l-carnosine derivative 
that has been synthesized at this point. It is easily transportable 
by PepT1 and not metabolized by CN1 (Figure 1), it maintains the 
outstanding safety profile of l-carnosine, and it was determined 
to be more reactive toward HNE, MGO, and ACR compared with 
l-carnosine (Tables 1 and 2 and Supplemental Table 2). As such, 
it represents a promising lead compound for counteracting RCS, 
particularly lipid peroxidation–derived α,β-unsaturated alde-
hydes, which have recently come to the forefront as primary driv-
ing forces in chronic disease.
Conclusions and translational perspective. The present study 
supports the hypothesis that sugar- and lipid-derived RCS have 
a causal role in metabolic disorders associated with obesity and 
further demonstrates that carnosinol represents a very promising 
lead compound in a new class of RCS-scavenging agents derived 
from the histidyl dipeptide l-carnosine.
Methods
A more detailed description of the materials and methods used in this 
study can be found in the supplemental material.
Materials and reagents. Solvents for HPLC and LC-MS and all ana-
lytical-grade chemicals were purchased from Sigma-Aldrich. l-car-
nosine and carnosinol were gifts of Renato Canevotti and Stefania 
Gagliardia (Flamma S.p.A.). For molecular and biochemical endpoints, 
all reagents were from Sigma-Aldrich unless otherwise noted above.
ADMET studies. ADMET studies were performed by Nikem 
Research following standard experimental protocols. PK studies were 
performed using fasted CD male rats obtained from Charles River 
ic patients (15). In the present study, we used male GPx4+/– mice 
as a model to pharmacologically assess carnosinol in a context of 
enhanced lipid peroxidation–induced by obesity. As shown in Fig-
ure 5, GPx4+/– mice had greater levels of HNE adducts in skeletal 
muscle and pancreas following a HFHS diet compared with levels 
in WT mice. Carnosinol was effective at mitigating HNE adducts 
in these organs from both WT and GPx4+/– mice but was only fully 
effective at mitigating insulin sensitivity and glucose tolerance in 
WT mice. A reason for this may be that the dose of carnosinol used 
in this study was insufficient for a complete therapeutic effect 
in the GPx4+/– mice. Evidence supporting this conclusion is that 
there was a greater concentration of the carnosinol-ACR adduct 
in HFHS-fed GPx4+/– livers (Figure 7A), which corresponded with 
a lower concentration of free carnosinol in the livers and kidneys 
of HFHS-fed GPx4+/– mice (Supplemental Table 5). These findings 
are consistent with a greater aldehyde load in the GPx4+/– mice on 
a HFHS diet and a correspondingly greater demand for carnosinol 
in these mice as compared with WT mice on a HFHS diet. Taken 
together, we have uncovered compelling evidence that the ther-
apeutic effect of carnosinol is mediated, at least in part, by its 
RCS-scavenging capacity.
Other compounds that scavenge RCS have shown significant 
therapeutic potential in preclinical studies using cardiovascular, 
renal, and metabolic disease models. Of all those tested to date, 
aminoguanidine and members of the B vitamin family (pyridox-
amine, thiamine) have shown the most promising therapeutic 
effects (29, 65). However, in randomized, controlled trials these 
compounds have yielded largely disappointing results (with the 
exception of pyridoxamine), probably because of their promis-
cuous reactivity to all aldehydes (e.g., pyridoxal). Such off-target 
effects, particularly in the case of aminoguanidine (66), have 
made existing RCS-scavenging therapies unsuitable for main-
stream clinical practice (67). These findings underscore the com-
plexity of carbonyl biochemistry in physiological systems and 
illustrate that, in principle, agents that scavenge or block RCS have 
clinical potential. Thus, the development of novel RCS-scaveng-
ing therapies is warranted.
Recently, interventional studies based on a daily dose of l-car-
nosine (2 g/day for 12 weeks) in overweight and obese subjects 
resulted in the preservation of insulin sensitivity and insulin secre-
tion and normalized glucose tolerance compared with the place-
bo group. Furthermore, l-carnosine supplementation reduced 
2-hour insulin levels after oral glucose tolerance tests (OGTTs) in 
a subgroup of individuals with impaired glucose tolerance (68). 
Although l-carnosine was not detected in serum, it was easily 
detectable in the urine as a conjugate with ACR (69). The in vivo 
RCS-scavenging capacity of l-carnosine was further confirmed by 
2 independent studies reporting the presence of covalent adducts 
between carnosine and lipid peroxidation by-products (e.g., ACR, 
HNE, HHE) in the urine of human volunteers (70, 71).
Given the findings of these translational studies, it would seem 
that orally supplemented l-carnosine, despite its rapid serum deg-
radation by carnosinases, provides a promising therapeutic effect 
in obese subjects, one that may be linked to a RCS-scavenging 
mechanism. However, several studies indicate that the benefi-
cial effect of l-carnosine is strictly associated with its serum sta-
bility and bioavailability. An allelic variant of CN1 that results in 
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test. This allowed us to compare the main effects of the treatment 
within each genotype and to ascertain whether there were interactions 
between the genotype and the treatment. A P value of less than 0.05 
was considered statistically significant.
Study approval. All in vivo studies were performed in accordance 
with Italian law (D.L.vo 116/92). All aspects of this study involving the 
care and use of laboratory animals received IACUC approval from the 
University of Milan in accordance with Italian law (D. L.vo 116/92) and 
with the guidelines of the Association for Assessment and Accredita-
tion of Laboratory Animal Care (AAALAC) in the United States. Stud-
ies in rat models were approved by the animal ethics committee of 
the University of Milan and communicated to the Italian Ministry of 
Health, corresponding to article seven of D.L. 116/92. Studies using 
mouse models were performed with the approval of the IACUC of East 
Carolina University, in compliance with NIH guidelines for the care 
and use of laboratory animals.
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Rodent models of obesity and metabolic syndrome. Both rat and 
mouse models of diet-induced obesity were used in this study. Eight-
week-old male Sprague-Dawley rats (Harlan Laboratories) weighing 
200 ± 20 g were used for this study. Rats were housed under constant 
environmental conditions and were fed standard laboratory rat chow 
or a 60% HF diet (Mucedola S.R.L.) and tap water ad libitum. In par-
ticular, the control diet contained 60% corn starch (carbohydrates), 
20% casein (protein), 0.3% methionine, 5% lard (fat), 8% cellulose, 
5% mineral mixture and 1% vitamin mixture, and zinc carbonate 
0.004%. The fructose diet contained all the ingredients except corn 
starch, which was replaced by an equal quantity of fructose. Animals 
were acclimatized for a period of at least 7 days before use in the study. 
Subsequently, rats were randomly divided into 5 groups. The control 
group received a standard rat chow diet for 6 weeks, whereas the oth-
er 4 groups of mice were given a fructose-enriched diet for 6 weeks. 
Three weeks after starting the fructose diet, two groups were treated 
with carnosinol at two doses: 10 and 45 mg/kg/day. An additional 
group was treated with 10 mg/kg/day rosiglitazone (GlaxoSmith-
Klein), and the fifth group continued with the fructose-enriched diet 
alone (HF group). Rosiglitazone was orally administered to rats by gas-
tric gavage during the last 3 weeks of the study, while carnosinol was 
dissolved in the water. During all the experiments, rats had ad libitum 
access to food and water.
For mouse models of diet-induced obesity, C57BL6/J female mice 
(The Jackson Laboratory) were crossed with male GPx4+/– mice, and 
the pups were genotyped by PCR using previously described primers 
(15). At 8 to 12 weeks of age, WT and GPx4+/– male age-matched lit-
termates were randomly assigned to groups and individually housed. 
Mice were fed either a control (TD110367) or a HFHS (TD110365) 
diet from Harlan-Teklad Laboratories ad libitum for 25 weeks. The 
composition of this diet was a special formulation consisting of mixed 
saturated and n-6 PUFA (44.6% kcal/g fat), with a high-sucrose (34% 
kcal/g) content (54). After 8 weeks of the HFHS diet, half of the mice 
in the HFHS diet cohort (WT and GPx4+/–) were administered carnosi-
nol (45 mg/kg/day) in their drinking water until study termination at 
20 weeks. This dose was calculated on the basis of a series of days on 
which water consumption was meticulously recorded, and the dose of 
carnosinol was maintained and adjusted according to the body weight 
of each mouse throughout the duration of the study.
Statistics. Data from our in vitro analyses are presented as the mean 
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